Aspira Pathlab profit collapses to ₹5 lakh as Q4 losses mount
Annual revenue grew 13.6% to ₹24.98 crore, but bottom-line performance eroded significantly due to a ₹68.91 lakh loss in the final quarter.
What's new
- FY26 profit dropped to ₹5.13 lakh from ₹2.07 crore despite a 13.6% revenue rise.
- A Q4 loss of ₹68.91 lakh wiped out most of the company's annual earnings.
- Vaibhav Odhekar, co-founder of POKKT, joins the board as an executive director.
Why this matters
For a company with a market cap of ₹59 crore, a profit collapse of this magnitude is a sharp reversal. The acquisition of Om Pathology Laboratory in Surat suggests a push for scale, but the immediate financial reality is a business struggling to maintain margins.
What we're watching
- Whether the Surat acquisition provides a revenue lift in the coming quarters.
- How the new executive director influences the company's growth strategy.
- If the Q4 loss is a one-time event or a sign of rising operational costs.
The full read
Aspira Pathlab & Diagnostics ended FY26 with a stark divergence between top-line growth and bottom-line stability. Revenue climbed 13.6% to ₹24.98 crore, yet net profit plummeted to ₹5.13 lakh from ₹2.07 crore a year earlier.
It is a brutal reversal.
The primary culprit is a ₹68.91 lakh loss recorded in the final quarter of the year, which effectively erased the gains made during the preceding nine months of operation. Amidst this financial pressure, the company is attempting a pivot toward expansion, finalizing the acquisition of Om Pathology Laboratory in Surat on February 1, 2026, while simultaneously appointing POKKT co-founder Vaibhav Odhekar to the board. For a nano-cap valued at ₹59 crore, the transition from a multi-crore profit to near-breakeven territory is the defining feature of these results. The next test is whether the Surat acquisition can reverse the margin erosion seen in the March quarter or if the company faces deeper structural headwinds.
Questions answered
- What caused the sharp drop in annual profit?
- While revenue grew by 13.6% to ₹24.98 crore, the company incurred a loss of ₹68.91 lakh in the March quarter. This quarterly deficit dragged the full-year profit down to ₹5.13 lakh.
- Did the auditor raise any concerns about these results?
- No. The statutory auditor issued an unmodified opinion on the standalone financial results.
- What is the status of the Om Pathology Laboratory acquisition?
- The acquisition of the Surat-based laboratory is complete, with the transaction becoming effective on February 1, 2026.
- Who is the new addition to the board?
- Vaibhav Odhekar, the co-founder of the mobile gaming platform POKKT, has been appointed as an additional executive director.